Studying drug resistance in chronic hepatitis B patients in Turkey
Part of Digestive system, Infections clinical trials.
This trial checks if certain hepatitis B virus mutations can cause resistance to entecavir, a common treatment. It looks at two groups: people who have never been treated and those who have taken lamivudine before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have hepatitis B (HBsAg positive).
- Either you have never taken hepatitis B drugs and your viral count is high (HBV DNA greater than 2000 IU/ml), or you have taken lamivudine for at least 6 months and then switched to another drug like adefovir, tenofovir disoproxil, or tenofovir alafenamide.
- You must be able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This study tests a new experimental drug called AHB-171 in people with chronic hepatitis B infection. The trial aims to see how safe the drug is and how well it works to help control the virus.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
Hear when a new Hepatitis B, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.